Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Ricardo D Parrondo & Taimur Sher. (2019) Prevention Of Skeletal Related Events In Multiple Myeloma: Focus On The RANK-L Pathway In The Treatment Of Multiple Myeloma. OncoTargets and Therapy 12, pages 8467-8478.
Read now
Read now
Shaji K. Kumar. (2015) Bisphosphonates in multiple myeloma: a fractured consensus. Leukemia & Lymphoma 56:3, pages 553-554.
Read now
Read now
Articles from other publishers (27)
Martin Johansen, Mette Bøegh Levring, Kasper Stokbro, Marta Diaz-delCastillo, Abdul Ahad Khan, Line Adsbøll Wickstroem, Michael Tveden Gundesen, Ida Bruun Kristensen, Charlotte Guldborg Nyvold, Mikkel Østerheden Andersen, Thomas Levin Andersen, Niels Abildgaard & Thomas Lund. (2023) Novel Developments in the Treatment of Multiple Myeloma-Associated Bone Disease. Cancers 15:23, pages 5585.
Crossref
Crossref
Munawwar Hussain, Fatima Khan & Samer Al Hadidi. (2023) The use of bone-modifying agents in multiple myeloma. Blood Reviews 57, pages 100999.
Crossref
Crossref
Parthasarathy Seshacharyulu, Sushanta Halder, Ramakrishna Nimmakayala, Satyanarayana Rachagani, Sanjib Chaudhary, Pranita Atri, Ramakanth Chirravuri-Venkata, Michel M. Ouellette, Joseph Carmicheal, Shailendra K. Gautam, Raghupathy Vengoji, Shuo Wang, Sicong Li, Lynette Smith, Geoffrey A. Talmon, Kelsey Klute, Quan Ly, Bradley N Reames, Jean L Grem, Lyudmyla Berim, James C Padussis, Sukhwinder Kaur, Sushil Kumar, Moorthy P. Ponnusamy, Maneesh Jain, Chi Lin & Surinder K Batra. (2022) Disruption of FDPS/Rac1 axis radiosensitizes pancreatic ductal adenocarcinoma by attenuating DNA damage response and immunosuppressive signalling. eBioMedicine 75, pages 103772.
Crossref
Crossref
Ioannis Ntanasis-Stathopoulos & Evangelos Terpos. 2022. Bone Cancer. Bone Cancer
1019
1029
.
Divaya Bhutani, Rajshekhar Chakraborty & Suzanne Lentzsch. 2022. Hypercalcemia. Hypercalcemia
157
169
.
Tina Bech Olesen, Ina Trolle Andersen, Anne Gulbech Ording, Vera Ehrenstein, Anouchka Seesaghur, Carsten Helleberg, Trine Silkjær, Rohini K. Hernandez, Daniela Niepel & Niels Abildgaard. (2021) Use of bisphosphonates in multiple myeloma patients in Denmark, 2005–2015. Supportive Care in Cancer 29:8, pages 4501-4511.
Crossref
Crossref
Andrew H. Tam, Allison J. Schepers, Angel Qin & Victoria R. Nachar. (2020) Impact of Extended-Interval Versus Standard Dosing of Zoledronic Acid on Skeletal Events in Non–Small-Cell Lung Cancer and Small-Cell Lung Cancer Patients With Bone Metastases. Annals of Pharmacotherapy 55:6, pages 697-704.
Crossref
Crossref
Evangelos Terpos & Ioannis Ntanasis‐Stathopoulos. (2020) Controversies in the use of new bone‐modifying therapies in multiple myeloma. British Journal of Haematology 193:6, pages 1034-1043.
Crossref
Crossref
Evangelos Terpos, Elena Zamagni, Suzanne Lentzsch, Matthew T Drake, Ramón García-Sanz, Niels Abildgaard, Ioannis Ntanasis-Stathopoulos, Fredrik Schjesvold, Javier de la Rubia, Charalampia Kyriakou, Jens Hillengass, Sonja Zweegman, Michele Cavo, Philippe Moreau, Jesus San-Miguel, Meletios A Dimopoulos, Nikhil Munshi, Brian G M Durie & Noopur Raje. (2021) Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group. The Lancet Oncology 22:3, pages e119-e130.
Crossref
Crossref
Ashley McEwan & Silvia CW Ling. 2021. Resistance to Targeted Therapies in Multiple Myeloma. Resistance to Targeted Therapies in Multiple Myeloma
105
127
.
Jeffrey W. Chadwick, Howard C. Tenenbaum, Chun-Xiang Sun, Robert E. Wood & Michael Glogauer. (2020) The effect of pamidronate delivery in bisphosphonate-naïve patients on neutrophil chemotaxis and oxidative burst. Scientific Reports 10:1.
Crossref
Crossref
Stine Rasch, Thomas Lund, Jon Thor Asmussen, Anne Lerberg Nielsen, Rikke Faebo Larsen, Mikkel Østerheden Andersen & Niels Abildgaard. (2020) Multiple Myeloma Associated Bone Disease. Cancers 12:8, pages 2113.
Crossref
Crossref
Tri Giang Phan & Peter I. Croucher. (2020) The dormant cancer cell life cycle. Nature Reviews Cancer 20:7, pages 398-411.
Crossref
Crossref
Mei Mei, Zijian Xiang, Jinghua Yang & Ruolan Xiang. (2020) Efficacy of zoledronic acid for prevention of bone loss in early-stage breast cancer patients receiving adjuvant therapy: A meta-analysis of 13 randomized controlled trials. Current Problems in Cancer 44:2, pages 100507.
Crossref
Crossref
Niall M Byrne, Matthew A Summers & Michelle M McDonald. (2019) Tumor Cell Dormancy and Reactivation in Bone: Skeletal Biology and Therapeutic Opportunities. JBMR Plus 3:3, pages e10125.
Crossref
Crossref
Qiao-Hong Zhao, Xi-Shan Zhang, Kun Wu, Jie Zhang, Tian-Fang Xia, Jian Chen, Zhen-Shen Qin & Li-Qun Pang. (2018) Preparation of Zoledronate liposome and its impact on apoptosis of Kupffer cells in rat liver. Acta Cirurgica Brasileira 33:12, pages 1052-1060.
Crossref
Crossref
Chen Tian, Lu Wang, Ling Wu, Lei Zhu, Wengui Xu, Zhaoxiang Ye, Zhigang Zhao, Yafei Wang & Yizhuo Zhang. (2018) Clinical characteristics and prognosis of multiple myeloma with bone-related extramedullary disease at diagnosis. Bioscience Reports 38:3.
Crossref
Crossref
Elizabeth S. Ring, Michelle A. Lawson, John A. Snowden, Ingrid Jolley & Andrew D. Chantry. (2017) New agents in the Treatment of Myeloma Bone Disease. Calcified Tissue International 102:2, pages 196-209.
Crossref
Crossref
Meletios A Dimopoulos & Amy S Kimball. (2018) Carfilzomib for relapsed or refractory multiple myeloma – Authors' reply. The Lancet Oncology 19:1, pages e2.
Crossref
Crossref
Oi Lin Lee, Noemi Horvath, Cindy Lee, Doug Joshua, Joy Ho, Jeff Szer, Hang Quach, Andrew Spencer, Simon Harrison, Peter Mollee, Andrew W. Roberts, Dipti Talaulikar, Ross Brown, Bradley Augustson, Silvia Ling, Wilfrid Jaksic, John Gibson, Anna Kalff, Anna Johnston, Akash Kalro, Chris Ward, H. Miles Prince & Andrew Zannettino. (2017) Bisphosphonate guidelines for treatment and prevention of myeloma bone disease. Internal Medicine Journal 47:8, pages 938-951.
Crossref
Crossref
Françoise Debiais, Justine Vix, Géraldine Durand & Isabelle Azaïs. (2017) Prise en charge des lésions osseuses du myélome multiple : quelles particularités ?. Revue du Rhumatisme Monographies 84:2, pages 197-204.
Crossref
Crossref
Agustin Avilès, Maria-Jesùs Nambo, Judith Huerta-Guzmàn, Sergio Cleto & Natividad Neri. (2017) Prolonged Use of Zoledronic Acid (4 Years) Did Not Improve Outcome in Multiple Myeloma Patients. Clinical Lymphoma Myeloma and Leukemia 17:4, pages 207-210.
Crossref
Crossref
Kristen Marie SanfilippoJesse KellerBrian F. GageSuhong LuoTzu-Fei WangGerald MoskowitzJason GumbelBrandon BlueKatiuscia O’BrianKenneth R. Carson. (2016) Statins Are Associated With Reduced Mortality in Multiple Myeloma. Journal of Clinical Oncology 34:33, pages 4008-4014.
Crossref
Crossref
Rebecca Silbermann & Garson David Roodman. (2016) Current Controversies in the Management of Myeloma Bone Disease. Journal of Cellular Physiology 231:11, pages 2374-2379.
Crossref
Crossref
Heleen H. Van Acker, Sébastien Anguille, Yannick Willemen, Evelien L. Smits & Viggo F. Van Tendeloo. (2016) Bisphosphonates for cancer treatment: Mechanisms of action and lessons from clinical trials. Pharmacology & Therapeutics 158, pages 24-40.
Crossref
Crossref
Mahitab Elsayed, Daisuke Kobayashi, Toshio Kubota, Naoya Matsunaga, Ryusei Murata, Yuko Yoshizawa, Natsuki Watanabe, Tohru Matsuura, Yuya Tsurudome, Takashi Ogino, Shigehiro Ohdo & Takao Shimazoe. (2016) Synergistic Antiproliferative Effects of Zoledronic Acid and Fluvastatin on Human Pancreatic Cancer Cell Lines: An <i>in Vitro</i> Study. Biological & Pharmaceutical Bulletin Biological and Pharmaceutical Bulletin 39:8, pages 1238-1246.
Crossref
Crossref
Michel D. Wissing. (2015) Chemotherapy- and Irradiation-Induced Bone Loss in Adults with Solid Tumors. Current Osteoporosis Reports 13:3, pages 140-145.
Crossref
Crossref